Susquehanna International Group, LLP Arbutus Biopharma Corp Call Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$2.52 - $3.63 $2.83 Million - $4.07 Million	-1,121,900 Reduced 90.56%	117,000 $361,000
Q1 2024 May 07, 2024	BUY	$2.26 - $2.92 $2.42 Million - $3.13 Million	1,072,900 Added 646.33%	1,238,900 $3.2 Million
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $159,874 - $240,284	94,600 Added 132.49%	166,000 $415,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $2.27 $69,540 - $83,082	-36,600 Reduced 33.89%	71,400 $144,000
Q2 2023 Aug 11, 2023	SELL	$2.24 - $3.06 $520,576 - $711,144	-232,400 Reduced 68.27%	108,000 $248,000
Q1 2023 May 16, 2023	BUY	$2.23 - $3.1 $458,265 - $637,050	205,500 Added 152.34%	340,400 $1.03 Million
Q4 2022 Feb 14, 2023	SELL	$1.91 - $2.85 $19,673 - $29,355	-10,300 Reduced 7.09%	134,900 $314,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $744,856 - $1.14 Million	-396,200 Reduced 73.18%	145,200 $277,000
Q2 2022 Aug 15, 2022	BUY	$1.98 - $3.17 $186,120 - $297,980	94,000 Added 21.01%	541,400 $1.47 Million
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $97,768 - $160,792	-40,400 Reduced 8.28%	447,400 $1.33 Million
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $269,948 - $400,148	86,800 Added 21.65%	487,800 $1.9 Million
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $127,465 - $222,222	48,100 Added 13.63%	401,000 $1.72 Million
Q2 2021 Aug 11, 2021	BUY	$2.5 - $3.51 $413,750 - $580,905	165,500 Added 88.31%	352,900 $1.07 Million
Q1 2021 May 17, 2021	SELL	$3.14 - $4.84 $1.1 Million - $1.7 Million	-350,500 Reduced 65.16%	187,400 $624,000
Q4 2020 Feb 16, 2021	BUY	$2.76 - $4.97 $1.07 Million - $1.92 Million	386,200 Added 254.58%	537,900 $1.91 Million
Q3 2020 Nov 16, 2020	BUY	$1.75 - $6.2 $218,750 - $775,000	125,000 Added 468.16%	151,700 $475,000
Q2 2020 Aug 14, 2020	BUY	$0.91 - $2.36 $13,195 - $34,220	14,500 Added 118.85%	26,700 $49,000
Q1 2020 May 15, 2020	SELL	$1.01 - $3.42 $64,741 - $219,222	-64,100 Reduced 84.01%	12,200 $12,000
Q4 2019 Feb 14, 2020	BUY	$0.87 - $2.89 $56,724 - $188,428	65,200 Added 587.39%	76,300 $212,000
Q2 2019 Aug 14, 2019	SELL	$1.46 - $4.44 $148,628 - $451,992	-101,800 Reduced 90.17%	11,100 $23,000
Q1 2019 May 15, 2019	BUY	$3.41 - $4.57 $325,655 - $436,435	95,500 Added 548.85%	112,900 $404,000
Q4 2018 Feb 14, 2019	SELL	$3.5 - $9.66 $52,500 - $144,900	-15,000 Reduced 46.3%	17,400 $67,000
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $321,065 - $505,115	-40,900 Reduced 55.8%	32,400 $306,000
Q2 2018 Aug 14, 2018	SELL	$5.0 - $7.35 $172,000 - $252,840	-34,400 Reduced 31.94%	73,300 $535,000
Q1 2018 May 15, 2018	BUY	$4.4 - $6.05 $403,920 - $555,390	91,800 Added 577.36%	107,700 $539,000
Q4 2017 Feb 14, 2018	BUY	$4.45 - $7.7 $6,230 - $10,780	1,400 Added 9.66%	15,900 $80,000
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $49,300 - $101,500	14,500	14,500 $90,000

Others Institutions Holding ABUS

# of Institutions

138

Shares Held

95.4M

Call Options Held

3.44M

Put Options Held

377K

Morgan Stanley New York, NY

21M
Shares

$82.6 Million
0.01% of portfolio
Whitefort Capital Management, LP New York, NY

12.9M
Shares

$50.7 Million
30.08% of portfolio
Black Rock Inc. New York, NY

11.6M
Shares

$45.5 Million
0.0% of portfolio
Two Seas Capital LP Rye, NY

8.57M
Shares

$33.8 Million
10.59% of portfolio
Vanguard Group Inc Valley Forge, PA

7.02M
Shares

$27.7 Million
0.0% of portfolio

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $591M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account